Arrakis spices up development efforts with $75M Series B round for RNAtargeting drugs

Arrakis spices up development efforts with $75M Series B round for RNA-targeting drugs

The company has raised more than $100 million since 2017 and plans to use the current funding to build a pipeline of RNA-targeting small molecules.

More From BioPortfolio on "Arrakis spices up development efforts with $75M Series B round for RNA-targeting drugs"